Topical antineoplastics

Definition and Clinical Scope

Topical antineoplastics are pharmacologic agents formulated for direct application to the skin or mucous membranes to treat localized neoplastic lesions. These agents act primarily through cytotoxic, antimetabolic, or immunomodulatory mechanisms and are used in the management of pre-malignant and malignant dermatologic conditions. By delivering the active compound locally, topical antineoplastics allow for high tissue concentrations at the lesion site while limiting systemic exposure, reducing the risk of systemic toxicity.

These agents are used predominantly in conditions such as actinic keratosis (AK), superficial basal cell carcinoma (sBCC), Bowen’s disease (squamous cell carcinoma in situ), cutaneous T-cell lymphoma (CTCL), genital warts (HPV-related lesions), and certain superficial skin metastases.

---

Mechanisms of Action

Topical antineoplastics exert their effects through a variety of mechanisms:

• DNA synthesis inhibition (e.g., 5-fluorouracil)

• Immunomodulation and cytokine induction (e.g., imiquimod)

• Epigenetic regulation (e.g., diclofenac – indirect via COX inhibition)

• Protein and nucleic acid alkylation (e.g., mechlorethamine)

• Cellular apoptosis induction and antiviral activity (e.g., ingenol mebutate)

---

Common Topical Antineoplastic Agents

1. 5-Fluorouracil (5-FU)

   • Mechanism: Antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis.

   • Indications: Actinic keratosis, superficial basal cell carcinoma, Bowen's disease.

   • Formulations: 0.5%, 1%, and 5% creams or solutions.

   • Regimen: Applied once or twice daily for 2–6 weeks depending on lesion severity.

   • Adverse effects: Local inflammation, erosion, burning, crusting; photosensitivity.

   • Brands: Efudix, Carac, Fluoroplex, Tolak.

2. Imiquimod

   • Mechanism: Toll-like receptor 7 agonist, stimulates innate and adaptive immune responses, leading to interferon-α, interleukin-12, and TNF-α release.

   • Indications: Actinic keratosis, superficial basal cell carcinoma, external genital warts, molluscum contagiosum (off-label), Bowen’s disease.

   • Formulations: 2.5%, 3.75%, 5% cream.

   • Regimen: Applied 2–5 times/week for 6–16 weeks depending on indication.

   • Adverse effects: Erythema, erosion, ulceration, flu-like symptoms (systemic absorption rare).

   • Brands: Aldara, Zyclara.

3. Mechlorethamine (Nitrogen Mustard)

   • Mechanism: Alkylating agent that causes DNA crosslinking, inhibiting DNA replication and transcription.

   • Indications: Mycosis fungoides (cutaneous T-cell lymphoma).

   • Formulations: 0.016% gel.

   • Regimen: Applied once daily; occlusive dressing not required.

   • Adverse effects: Dermatitis, contact sensitization, pruritus, secondary malignancy risk (long-term use).

   • Brands: Valchlor.

4. Ingenol Mebutate (withdrawn in EU, still available in select markets)

   • Mechanism: Induces rapid lesion necrosis followed by immune cell infiltration.

   • Indications: Actinic keratosis.

   • Formulations: 0.015% (face/scalp), 0.05% (trunk/extremities).

   • Regimen: Once daily for 2–3 days.

   • Adverse effects: Intense erythema, swelling, vesiculation, ulceration; systemic absorption minimal.

   • Brands: Picato (withdrawn due to potential cancer risk).

5. Diclofenac Sodium (3%) + Hyaluronic Acid Gel

   • Mechanism: Inhibits COX-2, reduces prostaglandin-mediated proliferation in actinic keratosis; possible modulation of apoptosis and angiogenesis.

   • Indications: Actinic keratosis.

   • Formulation: 3% gel.

   • Regimen: Twice daily for 60–90 days.

   • Adverse effects: Mild irritation, photosensitivity.

   • Brands: Solaraze.

6. Resiquimod (under investigation)

   • Mechanism: Toll-like receptor 7/8 agonist (broader than imiquimod), induces stronger cytokine release.

   • Indications (investigational): AK, HPV-related warts, sBCC, CTCL.

   • Status: Experimental in topical neoplastic conditions.

---

Clinical Applications and Conditions Treated

1. Actinic Keratosis (AK)

   • All agents mentioned except mechlorethamine are approved for AK.

   • Preferred for field cancerization (multiple lesions across a sun-exposed area).

   • Treatment choice depends on lesion burden, patient age, cosmetic expectations, and tolerance.

2. Superficial Basal Cell Carcinoma (sBCC)

   • Imiquimod and 5-FU used for superficial, well-demarcated lesions <2 cm in diameter.

   • Surgery remains first-line; topical options for non-surgical candidates or low-risk sites.

3. Cutaneous T-cell Lymphoma (CTCL)

   • Mechlorethamine gel (Valchlor) is the only FDA-approved topical antineoplastic.

   • Imiquimod used off-label for patch/plaque stages of CTCL.

4. Bowen’s Disease

   • Topical 5-FU and imiquimod are both used for intraepidermal squamous cell carcinoma in situ.

5. Genital and Perianal Warts (Condyloma Acuminata)

   • Imiquimod 5% cream applied 3 times per week for up to 16 weeks.

6. Other Off-label Uses

   • Molluscum contagiosum: Imiquimod.

   • Skin metastases from breast cancer: Topical 5-FU (limited data).

---

Pharmacokinetics and Site-Specific Use

• Absorption is generally limited with proper topical application.

• Site-specific factors (e.g., thin skin on face or intertriginous areas) may enhance penetration.

• Occlusion may increase drug absorption, especially for agents like 5-FU.

• Local irritation is common but expected and sometimes indicative of therapeutic activity (e.g., with imiquimod).

---

Adverse Reactions and Monitoring

• Local Cutaneous Reactions: Most agents cause erythema, burning, erosion, crusting, and pruritus.

• Systemic Symptoms: Rare but may occur with imiquimod or extensive application of 5-FU (flu-like symptoms, fever, myalgia).

• Photosensitivity: Common with diclofenac, 5-FU; sun protection advised.

• Secondary Infections: Open skin erosions may lead to bacterial colonization.

• Allergic Contact Dermatitis: Particularly with imiquimod and mechlorethamine.

• Secondary Malignancy (theoretical): Long-term use of alkylating agents (e.g., mechlorethamine).

---

Drug Interactions

• Imiquimod:

  • Avoid concurrent use with systemic immunosuppressants (e.g., corticosteroids, methotrexate) as these may blunt immune response.

  • Possible synergistic effect with photodynamic therapy (off-label).

• 5-FU:

  • Avoid dihydropyrimidine dehydrogenase (DPD) inhibitors, which may increase systemic 5-FU exposure, though this is more relevant in systemic administration.

• Mechlorethamine:

  • Topical corticosteroids may reduce efficacy if applied concomitantly.

• Diclofenac:

  • NSAID sensitization risk in known hypersensitivity.

• Ingenol Mebutate:

  • Avoid with immunomodulators; potential additive irritation.

---

Precautions and Contraindications

• Pregnancy and Breastfeeding:

  • Most agents (e.g., 5-FU, imiquimod, tazarotene) are contraindicated or not recommended due to limited safety data.

• Photosensitivity:

  • Patients should avoid UV exposure and use high-SPF sunscreen during and after therapy.

• Immunocompromised Patients:

  • Use caution with imiquimod due to risk of exaggerated immune response or ineffectiveness.

---

Special Populations

• Pediatric Use:

  • Limited data; imiquimod sometimes used off-label for molluscum contagiosum.

• Elderly:

  • Generally safe with proper monitoring; increased risk of irritation due to thinner skin.

---

Clinical Monitoring

• Treatment Response:

  • Lesion resolution, crusting, erythema are expected during therapy.

  • Histopathologic clearance often used for confirmation in sBCC or Bowen’s disease.

• Adverse Events:

  • Monitor for excessive irritation, ulceration, infection.

• Post-treatment Surveillance:

  • Follow-up for recurrence, particularly in premalignant and malignant lesions.

---

Regulatory Status and Availability

• FDA-approved agents:

  • 5-FU (Efudex, Carac)

  • Imiquimod (Aldara, Zyclara)

  • Mechlorethamine (Valchlor)

  • Diclofenac (Solaraze)

• EMA approval similar, except ingenol mebutate withdrawn in 2020 due to possible skin cancer risk.

• OTC availability: None; all require prescription.

---

Representative Brand and Generic Names

Generic Name	Brand Name(s)	Indication(s)
Fluorouracil	Efudix, Carac, Tolak	AK, sBCC, Bowen’s disease
Imiquimod	Aldara, Zyclara	AK, sBCC, warts, CTCL (off-label)
Mechlorethamine	Valchlor	Mycosis fungoides (CTCL)
Diclofenac 3%	Solaraze	Actinic keratosis
Ingenol mebutate	Picato (withdrawn)	Actinic keratosis